IngredientsCandida species are classified as yeasts belonging to the phylum Ascomycota. They are commensal yeasts found on the skin, mucous membranes, gastrointestinal tract, blood, and vagina of animals and humans. The genus Candida encompasses a broad diversity of fungal species. Over 200 species of Candida have been identified, with approximately 20 known to cause human infections. Candida albicans (C. albicans) is the predominant species worldwide and tends to be susceptible to most of the limited number of widely used antifungal antibiotics.
Candida albicans is considered the most common opportunistic pathogenic fungus in humans and a causative agent of 60% of mucosal infections and 40% of candidemia cases. Other clinically significant species include C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei. Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis account for 80% to 90% of fungal isolates encountered worldwide.
The polymorphic fungus Candida albicans belongs to the normal flora of human mucosa and in most individuals is considered a non-pathogenic commensal. A defining biological feature is its dimorphism: the morphological transition between yeast and pseudohyphae (known as dimorphism), production of secretory enzymes such as Saps and phospholipase, and formation of biofilm are significant virulence factors contributing to C. albicans pathogenesis.
Species of Candida that are pathogenic for humans exist as benign commensals in their host organisms, in one or more body locations. As opportunistic pathogens, they are poised to overgrow cavities and penetrate tissue in response to an alteration in host physiology that presumably compromises the immune functions that normally suppress their growth.
In the dietary supplement and natural health marketplace, Candida itself is not marketed as an ingredient but rather as a target organism. Products sold under names such as "Candida Support" or "Candida Control" are formulations of natural agents intended to inhibit Candida growth. Such products typically consist of a combination of herbal ingredients (Pau D'Arco, Black Walnut and Oregano Oil), Biotin (a B-complex vitamin), and Caprylic Acid (a naturally occurring fatty acid derived from plant oils). These preparations are available as capsules, tablets, liquid drops, and delayed-release formulations. Delayed-release capsules or tablets protect sensitive ingredients from stomach acid, ensuring they reach the intestines intact, where Candida often thrives.
Candidiasis serves as the overarching term for a spectrum of fungal infections caused by yeasts of the genus Candida and represents the most common fungal infection worldwide. Candida species function as commensal organisms within the normal mycobiome, a fungal community that inhabits the skin, mucosal surfaces, and gastrointestinal tract. The mycobiome constitutes an essential component of the broader human microbiome. Disruption of microbial balance or impairment of host immune function allows Candida species to proliferate, invade host tissues, and produce clinical disease.
Approximately 45% of neonates, 45% to 65% of healthy children, 30% to 45% of healthy adults, and 50% to 65% of adults who wear removable dentures are colonized with C. albicans in the oral cavity.
In 50% of the population, C. albicans is part of the normal flora of the microbiota. Vulvovaginal candidiasis, primarily caused by Candida albicans, affects approximately 75% of women at least once in their lifetime, with 40%–50% experiencing recurrent episodes.
The global incidence of fungal infections has averaged one billion people, with more than 1.6 million deaths associated with overall fungal infections, and more than 1.5 million deaths from invasive fungal infections yearly. The predominant species causing candidemia remains Candida albicans, but it has declined from the majority species to causing less than 50% of U.S. cases. Increasing proportions of infections are being caused by C. glabrata, which now causes almost 30% of U.S. cases, as well as C. parapsilosis and other non-C. albicans species.
The mycobiome plays a critical role in immune system development, metabolic regulation, and maintenance of microbial homeostasis. Alterations within this fungal community, referred to as mycobiome dysbiosis, have demonstrated associations with multiple disease states, including inflammatory bowel disease, liver disease, and certain malignancies.
The recognition of Candida-associated conditions (oral thrush, vaginal discharge, skin infections) long preceded the modern identification of the organism, and traditional medicine systems worldwide developed plant-based remedies to manage these infections. Ethnomedicinal values of regional plants are reported since ancient times such as the medicines of the Egyptians (3000 BC; pharaohs), the Greeks (400 BC; Hippocrates), and the Romans (37 BC; Dioscorides). The constant therapeutic use of plants of the Arab peninsula was executed by Prophet Mohammad (571–632 AD); a tradition was established as The Prophetic Medicine (Al-Ṭibb al-Nabawi) by Ibn Qayyim al-Jawziyya, a practice still being used in folk medicine in the Arabian world. Medieval Persian physicians also contributed significantly: physicians such as Abu Bakr Muhammad ibn Zakaria Razi (865–925 AD) and Ibn Sina (980–1037 AD) produced encyclopedias on ethnomedicine such as The Law in Medicine (Al-Qanun Fi Al-Tibb).
Chinese herbal medicine has a long history of use in treating various infections, including those caused by Candida species. Recent studies have focused on the anti-fungal properties of traditional herbs. The formulation Longdan Xiegan decoction (LXD) was first documented by Wang Ang in the Qing Dynasty and has a wide range of applications in TCM practice. This traditional herbal formulation consists of 10 herbs and is currently a famous prescription used to ameliorate vulvovaginal candidiasis (VVC). Pulsatilla patens is a medicinal plant native to several countries and has been continuously used in TCM practice for centuries to treat various diseases, such as eye ailments, rheumatism, and skin eruptions.
Pau d'arco bark from the Tabebuia tree has been used in South American herbal traditions for centuries. Its active compounds, lapachol and beta-lapachone, have been subjects of modern antifungal research.
Multiple ethnobotanical studies document extensive traditional plant use for candidiasis management across Africa. In a study conducted in southern Benin, a total of 109 species of medicinal plants belonging to 44 families were listed and identified as traditionally used for candidiasis. In the Venda region of South Africa, the plant parts mostly used in therapeutic preparations were roots (27.7%), bark (23.2%), and a combination of roots, bark (18.7%) and leaves (14.3%). Decoctions (44.4%), infusions (20%), macerations (17.7%), burning (11.4%), and paste (6.5%) were the preparation methods used, and most herbal remedies were administered orally.
In Northern Uganda, most respondents (females, 95%) preferred herbal to western medication due to its perceived effectiveness, and there was high consensus among herbalists on herbal remedies for oral and vaginal candidiasis (FIC = 0.9).
Candida albicans is a common commensal fungus that colonizes the oropharyngeal cavity, gastrointestinal and vaginal tract, and healthy individuals' skin. In 50% of the population, C. albicans is part of the normal flora of the microbiota. The various clinical manifestations of Candida species range from localized, superficial mucocutaneous disorders to invasive diseases that involve multiple organ systems and are life-threatening. From systemic and local to hereditary and environmental, diverse factors lead to disturbances in Candida's normal homeostasis, resulting in a transition from normal flora to pathogenic and opportunistic infections.
Candida albicans is among the most prevalent fungal species of the human microbiota, asymptomatically colonizing several niches of the body, including the gastrointestinal tract, genitourinary tract, mouth, and skin. Immunocompromised health conditions, dysbiosis of the microbiota, or environmental changes, however, can lead to C. albicans overgrowth, causing infections that range from superficial mucosal infections to severe hematogenously disseminated infections.
Several virulence factors are known to be responsible for C. albicans infections, such as adherence to host and abiotic medical surfaces, biofilm formation, as well as secretion of hydrolytic enzymes. Moreover, C. albicans resistance to traditional antimicrobial agents, especially azoles, is well known, especially when Candida cells are in biofilm form.
Dimorphism (yeast-to-hyphae transition): The importance of the morphogenic transition from yeast to hyphae is shown by the fact that nonfilamentous C. albicans strains are avirulent. C. albicans tissue penetration is mediated by the invasive filamentous hyphae and is aided by candidal secreted proteolytic enzymes, which degrade epithelial cell barriers and facilitate hyphal penetration.
Biofilm formation: Formation of biofilm is a property of C. albicans pathogenesis. Most infections caused by C. albicans are related to the creation of a biofilm on the surface of the host or on abiotic surfaces (implants), which leads to high morbidity and mortality. Because C. albicans can transition from yeast to hyphae morphologically, its biofilm is a complex structure of different morphological forms.
Secreted hydrolases and toxins: The armory of virulence-related molecules that Candida fungi have at their disposal includes surface-located adhesins and invasins, atypical cell wall proteins (moonlighting proteins), cell wall polysaccharides — mannans, glucans, and chitin — secreted hydrolytic enzymes, toxins, and low molecular weight compounds like quorum sensing molecules and other secondary metabolites.
Biofilm-mediated drug resistance: Although planktonic C. albicans cells are not intrinsically resistant to clinically available antifungals, C. albicans biofilms exhibit inherent multidrug resistance. Cells comprising these biofilms overexpress efflux-pump encoding genes and are capable of expressing CDR1 and MDR1 during all developmental phases, which contributes to their robust resistance to azoles.
Risk factors for progression: The most common risk factors for invasive candidiasis include major surgery (especially involving the abdomen), immunosuppression, and supportive care measures used in critically ill patients, such as long-term broad spectrum antimicrobial therapy, central venous catheters, total parenteral nutrition, and renal replacement therapies.
The scientific literature on natural anti-Candida agents focuses on several key compound categories. These are the primary "active ingredients" in Candida-targeted supplement formulations.
Caprylic acid is a medium-chain saturated fatty acid (C8:0). Caprylic acid is a medium-chain fatty acid that is naturally found in mammalian breast milk and coconut oil. In vitro, it acts by disrupting the integrity of the Candida cell membrane, causing leakage of intracellular contents. Caprylic acid is part of the medium-chain triglyceride family of healthy fats. It can help to break down the cell walls of Candida, making it a promising supplement for addressing Candida overgrowth.
Several species of the genus Origanum have carvacrol and thymol (phenolic monoterpenes) among their main constituents; these are accompanied by other compounds such as ρ-cymene, γ-terpinolene, γ-terpinene, α-terpineol, linalool, 4-terpinol, germacrene-D and α-pinene, which are present in lower concentrations and also show antimicrobial activity. Oregano has antioxidant properties and exhibits antimicrobial activity against bacteria and fungi. Mechanisms of action of oregano essential oil vapor are related to membrane integrity and metabolic activity of Candida cells.
Berberine (BBR) is a bioactive herbal-originated alkaloid and has been reported to possess antifungal functions against C. albicans. In vitro studies have shown that berberine disrupts fungal glucose uptake by inhibiting hexokinase, an enzyme critical to Candida's energy metabolism. Unlike azole drugs — commonly prescribed antifungals — berberine does not induce resistance because it targets multiple metabolic pathways, making fungal adaptation difficult.
The well-known safety of cinnamaldehyde and eugenol for human use makes these two natural compounds candidates for the treatment of candidiasis. A pilot study evaluated the best composition of a mixture to be used against intestinal and vulvovaginal candidiasis, and in vivo studies are needed to confirm the encouraging in vitro results. Eugenol (4-allyl-2-methoxyphenol) is an aromatic compound extracted from clove essential oils that is used widely as a flavoring agent for foods and teas, as an herbal oil to treat toothache.
Phenols such as flavonoids and lignans have shown their antimicrobial potential. Silymarin, which is composed mainly of flavonolignans, has also been reported to show antimicrobial activities against various microorganisms. The antifungal effects of silymarin against clinical strains of C. albicans, C. krusei, and C. tropicalis have been demonstrated. Silymarin shows anti-virulence properties including the destabilization of mature biofilm and the inhibition of the secretion of hydrolases. qRT-PCR-based experiments demonstrated that the SAP4 gene involved in virulence was downregulated by silymarin.
Pau d'arco bark is derived from several species of South American Tabebuia trees. The key active naphthoquinone compounds, lapachol and beta-lapachone, have been the subject of laboratory-based antifungal research, with documented inhibitory effects on Candida species in experimental models, primarily in vitro.
Undecylenic acid is an unsaturated fatty acid derived from castor bean oil. Known as a strong Candida inhibitor, it has been used in topical antifungal creams and oral supplements for decades.
Probiotics contain lactic acid bacteria (LAB) strains that stabilize vaginal microbial balance, so they can be used as a complementary therapy along with conventional treatments to support VVC and prevent recurrence of infection. Saccharomyces boulardii supports balanced Candida levels in two ways: it breaks down the protective biofilm that Candida hides in to grow without the immune system interfering, and it crowds out Candida in the mycobiome.
Strength of evidence: Moderate for probiotics as adjunct; limited for most individual herbal agents in humans.
A 2024 systematic review evaluated 11 randomized controlled trials with a Jadad score greater than three, indicating high-quality studies based on criteria such as randomization, blinding, and dropout rates. The review demonstrated that probiotics, particularly Lactobacillus strains, showed significant improvements in clinical outcomes and vaginal microbiota restoration. However, variability in results highlights the need for further research.
Following the initial screening of 4,563 articles, a total of 25 clinical studies and seven systematic reviews were included in one analysis. The studies reviewed provide a generally positive yet inconsistent view of the efficacy of probiotics in managing VVC, including clinical, mycological response, and prevention perspectives.
Six RCTs were included in one systematic review and meta-analysis. Conflicting results have been reported regarding the benefit of probiotics in VVC.
A randomized controlled trial from India enrolled sixty patients newly diagnosed with VVC. Group A (30 patients) received oral fluconazole 150 mg single dose, while Group B (30 patients) received fluconazole plus oral probiotic capsules containing Lactobacillus rhamnosus, L. crispatus, L. gasseri, and L. jensenii for 2 months. No statistically significant difference between the clinical cure rate, mycological cure, and relapse rate was seen between the two groups; however, a larger proportion of patients in Group B (97%) achieved complete remission compared to Group A (90%).
Regarding vaginal probiotic applications, a vaginal probiotic gel with L. plantarum YUN-V2.0, L. pentosus YUN-V1.0, and L. rhamnosus YUN-S1.0 for 10 consecutive days showed a cure rate of 45%, which is below the expectations of a standard first-line treatment but still indicates that nearly half of patients were comfortable with the cream only, without the use of antifungals.
Regarding oregano essential oil for VVC, results from an in vitro and epithelium model study revealed high vapor-phase oregano essential oil antifungal activity. There was a significant reduction (>4 log CFU) in Candida species biofilms. Furthermore, the mechanisms of action were related to membrane integrity and metabolic activity, and the epithelium model confirmed effectiveness of vapor-phase oregano essential oil. However, these were laboratory findings only, and no clinical VVC human trials of oregano essential oil were identified in the searched sources.
A randomized controlled trial referenced in the literature found that garlic extract tablets were roughly as effective as the antifungal drug fluconazole for treating vaginal yeast infections, representing a gold-standard type of study. This was a single trial and the result requires independent replication.
Strength of evidence: Moderate for probiotics (meta-analysis level); limited for individual herbal agents.
A meta-analysis found that a combination of probiotics (a Lactobacillus/Bifidobacterium blend and various Saccharomyces species) reduced oral Candida counts in people with oral thrush. The quality of evidence supporting specific herbal agents for oral candidiasis in human clinical trials remains limited to isolated small studies.
C. albicans is responsible for numerous common infections in humans including vaginal yeast infections, thrush (oral candidiasis), esophagitis, gastrointestinal candidiasis, cutaneous candidiasis, diaper rash, paronychia (nail fold infection), chronic mucocutaneous candidiasis, and life-threatening systemic infections. In fact, C. albicans is the leading fungal infection in immunocompromised patients and is also one of the leading infections in patients with long hospital stays and indwelling catheters.
Strength of evidence: Preliminary; most supporting data are in vitro or animal models, with limited human clinical trials.
A clinical trial found that MCT oil, which is high in caprylic acid, reduced gut Candida in preterm infants. This represents a specific population, and generalizability to healthy adults with intestinal Candida overgrowth is uncertain. Clinical evidence suggests a potential link between C. albicans and certain chronic inflammatory bowel diseases, such as Crohn's disease.
Studies on Origanum vulgare essential oil show differences in susceptibility between fresh Candida isolates and standard strains, as well as between different Candida species, although these differences were not statistically significant in in vitro models.
Regarding berberine, in a microdilution test, the minimum inhibitory concentration (MIC) of berberine was found to be 16 μg/mL with a fractional inhibitory concentration index (FICI) of 0.13 in C. tropicalis, and the synergism of berberine with fluconazole was also confirmed microscopically. These are in vitro findings; clinical trials in gastrointestinal candidiasis remain sparse.
Strength of evidence: No evidence supports natural supplement use for invasive candidiasis. Conventional antifungal agents remain standard of care.
Candida albicans ranks as a leading cause of all healthcare-associated bloodstream infections in the United States, with a crude mortality rate of approximately 40% despite antifungal intervention. Infections caused by Candida species are a significant medical problem because they can disseminate to nearly every organ of the body. In addition, there are only a few classes of antifungal drugs available to treat patients with invasive fungal infections. No peer-reviewed evidence supports the use of natural or dietary supplement-based approaches as primary treatment for invasive or systemic candidiasis.
Strength of evidence: In vitro only; no clinical trial evidence identified in searched sources.
Silymarin suppressed the growth of cells of most of the tested clinical Candida albicans strains with MIC values between 30 and 1,200 µg/mL. Based on the fractional inhibitory concentration index (FICI), the combination of silymarin with antifungal drugs caspofungin, fluconazole, and amphotericin B did not significantly change the MIC values for the tested Candida strains. Furthermore, no antagonistic reactions were observed in any combination of drugs.
Strength of evidence: In vitro pilot study only; no human clinical evidence.
The well-known safety of cinnamaldehyde and eugenol for human use makes these two natural compounds candidates for the treatment of candidiasis. The pilot study evaluated the best composition of a mixture to be used against intestinal and vulvovaginal candidiasis; in vivo studies are needed to confirm the encouraging results.
Strength of evidence: Meta-analysis level for gastrointestinal indications generally; specific anti-Candida human evidence is limited.
Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5,029 study patients), S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms. The evidence base for S. boulardii is strongest for gastrointestinal dysbiosis, antibiotic-associated diarrhea, and C. difficile infection. Unlike other bacterial strains of probiotics, such as Enterococcus faecium and Lactobacillus rhamnosus, which have been shown to acquire antibiotic-resistance genes, S. boulardii has not developed any antibiotic or antifungal resistance. Direct human trial evidence specifically targeting Candida overgrowth with S. boulardii as the primary endpoint remains limited.
The following dosages are drawn only from published clinical trial literature or from formulation data reported in peer-reviewed sources. They should not be construed as recommendations.
Note: The evidence for most herbal anti-Candida agent dosages in humans is insufficient to draw firm conclusions. Most data derive from in vitro or animal studies. Only the probiotic dosages above are drawn from human clinical trials.
The prevalence of candidiasis has sharply increased globally over the last two decades. A gradual increase in resistance to antifungal drugs has been noted among non-albicans Candida spp., and as a result, clinical treatment with antifungal agents has become challenging. The emergence of C. auris, known for its multidrug resistance, presents additional challenges for treatment and infection control.
Candida infections that are associated with biofilms can withstand much higher concentrations of antifungal drugs compared with infections caused by planktonic cells, thus making biofilm infections particularly challenging to treat. Conventional treatments for BV and VVC, including antibiotics and antifungals, often fail to prevent recurrence owing to persistent biofilms and emerging drug resistance.
Fungal infections are increasingly concerning, particularly in immunocompromised patients. These patients often suffer from comorbidities and receive multiple, non-antifungal medications. A 2025 PMC study found that co-administered non-antifungal medications have the potential to influence antifungal drug efficacy, though the full extent of these effects are "poorly understood."
The major concern with candidiasis is that it is associated with a mortality rate of 10–49% in immunocompromised patients. Studies indicate an incidence of candidiasis ranging from around 10% to up to 52% among cancer patients, with strains of Candida spp. resistant to antifungal treatment contributing to high morbidity and mortality rates within this population, including cancer treatment complications. The use of natural anti-Candida supplements in such individuals has not been evaluated in adequately powered clinical trials, and unsupervised use in immunocompromised patients is a recognized clinical concern given the potential for disease progression if empirically effective antifungal therapy is delayed.
The use of a living organism as therapy increases theoretical risk in four general areas: transfer of antibiotic-resistance genes, translocation of the living organism from the intestine to other areas of the body, persistence in the intestines, and the development of adverse reactions. The first three concerns are of minimal impact on S. boulardii. Unlike other bacterial strains of probiotics, S. boulardii has not developed any antibiotic or antifungal resistance.
Selecting the most appropriate treatment is complicated by concerns about drug toxicity, potential interactions, antifungal resistance, and treatment costs. For instance, amphotericin B, while effective, is associated with severe nephrotoxicity, which can be exacerbated when used alongside other nephrotoxic drugs. Similarly, ketoconazole has been linked to serious, sometimes fatal, hepatotoxicity and nephrotoxicity. These considerations inform some patients' and clinicians' interest in adjunctive natural approaches, but natural supplement safety data in controlled clinical contexts remain sparse.
In vitro data suggest that some natural compounds can act synergistically with conventional antifungals. The synergism of berberine with fluconazole was confirmed in a microdilution test in a fluconazole-resistant C. tropicalis isolate. The combination of silymarin with antifungal drugs caspofungin, fluconazole, and amphotericin B did not significantly change the MIC values for tested Candida strains, and no antagonistic reactions were observed in any combination of drugs. These in vitro findings do not establish clinical safety or efficacy of combined natural–pharmaceutical antifungal therapy in humans.
The body of clinical evidence for natural anti-Candida supplementation is characterized by small sample sizes, heterogeneous populations, variable methodological quality, short durations, and limited standardization of botanical preparations. Variability in results highlights the need for further research. Longer-term studies are essential to assess the sustained impact of probiotic interventions on preventing vulvovaginal infections. For most herbal and fatty-acid agents discussed above, robust multicenter randomized controlled trials in well-defined human populations are lacking.
Health conditions that Candida may help support.
Body systems that Candida may help support.
Go back